APLS - Apellis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.68
-0.33 (-0.97%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close34.01
Open33.82
Bid31.09 x 1300
Ask34.00 x 1300
Day's Range32.34 - 33.82
52 Week Range16.85 - 45.04
Volume469,988
Avg. Volume1,042,804
Market Cap2.543B
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-6.39
Earnings DateJul 29, 2020 - Aug 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company approved the grant of an equity award to a new employee with a grant date of May 26, 2020, as an equity inducement award outside of the company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company. The equity award was approved on April 30, 2020, in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received an option to purchase 23,216 shares of Apellis common stock.

  • GlobeNewswire

    Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19

    Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company has initiated a Phase 1/2 clinical study of APL-9, an investigational C3 inhibitor designed for acute interventions, in COVID-19 patients with respiratory failure including acute respiratory distress syndrome (ARDS). In COVID-19, complement activation has also been found to be strongly associated with organ failure and thrombotic events, which involve the abnormal formation of blood clots and are an emerging cause of mortality in COVID-19 patients.2,3,4 Apellis initiated the Phase 1/2 study following preliminary results from its ongoing, non-interventional study in patients with ARDS secondary to COVID-19, which showed a substantial increase in the activation of the complement cascade.

  • GlobeNewswire

    Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced plans to submit a New Drug Application (NDA) for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the second half of 2020. Based on feedback from the U.S. Food and Drug Administration (FDA) during a pre-NDA meeting to discuss the registration strategy for pegcetacoplan, Apellis plans to submit the NDA with results from the Phase 3 PEGASUS trial comparing pegcetacoplan to eculizumab in patients with PNH.

  • GlobeNewswire

    Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress

    Results from positive Phase 3 PEGASUS study in PNH selected for oral presentation at the 2020 European Hematology Association CongressPEGASUS showed superiority of pegcetacoplan.

  • GlobeNewswire

    Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference

    Apellis Pharmaceuticals, Inc. (APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 8:20 a.m. ET. The conference will be held in a virtual meeting format. Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat.

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes

    Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it had entered into subscription agreements with a number of institutional investors for a private placement of $300.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “notes”) for an aggregate purchase price of $328.9 million. The private placement is expected to close on May 12, 2020, subject to satisfaction of customary closing conditions. The notes issuance is a reopening of, and will form a single series with, and have the same terms as, Apellis’ $220 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “existing notes”) issued on September 16, 2019, but will have a different issue date, issue price, CUSIP number and different restrictions on transfer.

  • GlobeNewswire

    Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results

    Full Enrollment of Two Phase 3 Trials in Geographic Atrophy Expected in the Second Quarter of 2020Meetings with US and EU Regulators to Discuss Submissions in Paroxysmal.

  • GlobeNewswire

    Apellis Reports Analysis from Phase 1b Geographic Atrophy Study

    Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced early data from the Phase 1b APL2-103 study of pegcetacoplan (APL-2) in patients with advanced geographic atrophy (GA) and low vision. The study, which enrolled 12 patients, was initiated to assess the safety of the Phase 3 formulation of pegcetacoplan (15mg/0.1mL). The analysis of APL2-103 has shown that the Phase 3 formulation was well tolerated over 12 months of treatment.

  • Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS)

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • GlobeNewswire

    Paul Fonteyne Joins Apellis Board of Directors

    Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today appointed Paul Fonteyne to its Board of Directors. Mr. Fonteyne’s appointment expands the Board to six directors, five of whom are independent. Mr. Fonteyne brings more than three decades of experience in the biopharmaceutical industry, including leadership roles in the United States and globally with Boehringer-Ingelheim, one of the world's leading pharmaceutical companies.

  • GlobeNewswire

    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

    Positive Top-line Results Announced from Head-to-Head Phase 3 PEGASUS Trial of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.

  • GlobeNewswire

    Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference

    WALTHAM, Mass., Feb. 26, 2020 -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the.

  • CEO council reveals innovation center location, plans international summit
    American City Business Journals

    CEO council reveals innovation center location, plans international summit

    Some of Louisville's most prominent and influential health care executives are members of this organization. It's moving forward with two strategic initiatives.

  • Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure
    American City Business Journals

    Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure

    With competition encroaching, Alexion executives are pushing plans to more than double the company’s product portfolio in the next three years, including at least one “high risk, high reward” drug candidate.

  • Apellis Pharmaceuticals' stock offering closes $50M higher than expected
    American City Business Journals

    Apellis Pharmaceuticals' stock offering closes $50M higher than expected

    The former Louisville-area company sold about 1.4 million more shares that were part of an option held by financial firms involved with the public stock offering.

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

    WALTHAM Mass., Jan. 13, 2020 -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of.

  • Apellis Pharmaceuticals, Inc. (APLS) vs. Hedge Fund Favorites in 2019
    Insider Monkey

    Apellis Pharmaceuticals, Inc. (APLS) vs. Hedge Fund Favorites in 2019

    We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57% each. Hedge funds' top 3 stock picks returned 45.7% last year and beat the S&P 500 ETFs by […]

  • Stock Market Rally Powers Higher Despite Iran Tensions; Tesla, Boeing, Costco, Beyond Meat In Focus: Weekly Review
    Investor's Business Daily

    Stock Market Rally Powers Higher Despite Iran Tensions; Tesla, Boeing, Costco, Beyond Meat In Focus: Weekly Review

    The stock market rally hit new highs despite an Iran missile attack. Tesla, Costco and Beyond Meat rallied. A Boeing 737 crash was just one of several big headlines for the aerospace giant.

  • Apellis Pharmaceuticals is planning to raise $350M — here's how
    American City Business Journals

    Apellis Pharmaceuticals is planning to raise $350M — here's how

    Apellis Pharmaceuticals Inc. is hoping to garner hundreds of millions of dollars in its latest public stock offering. The late-stage biopharmaceutical company disclosed late Wednesday that it will issue 9.5 million shares of common stock at $37 per share for potential gross proceeds of $351.5 million before certain deductions related to the public offerings. Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Evercore Group LLC are joint bookrunning managers and underwriters of the offering.

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $37.00 per share, for total gross proceeds of $351.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 1.425 million additional shares of its common stock at the public offering price, less the underwriting discount and commissions.

  • Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data
    Zacks

    Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data

    A low-key week for the biotech sector, with a few pipeline and regulatory updates.

  • Benzinga

    The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 7) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) (announced ...

  • Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study
    Zacks

    Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study

    Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.

  • This Biotech Just Topped Alexion's Biggest Moneymaker — And Rocketed
    Investor's Business Daily

    This Biotech Just Topped Alexion's Biggest Moneymaker — And Rocketed

    Shares of Apellis Pharmaceuticals rocketed Tuesday after the biotech company's experimental drug outperformed Alexion Pharmaceuticals' blockbuster, Soliris, in a head-to-head test.

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.